PTENdeficient

PTENdeficient refers to cells, tissues, or organisms that lack functional PTEN (phosphatase and tensin homolog) protein due to genetic mutations, deletions, or epigenetic silencing. PTEN is a dual-specificity phosphatase that antagonizes the PI3K/AKT signaling pathway by dephosphorylating PIP3, thereby suppressing cell growth, survival, and proliferation. Loss of PTEN activity results in constitutive activation of downstream kinases, promoting oncogenic processes such as uncontrolled cell division, resistance to apoptosis, and increased angiogenesis.

In human cancers, PTEN deficiency is observed across a broad spectrum of tumor types, including prostate, breast, endometrial, glioblastoma, melanoma, and colorectal cancers. Somatic PTEN mutations often involve truncating alterations, missense changes in the phosphatase domain, or promoter methylation, leading to reduced or absent protein expression. Germline PTEN mutations cause Cowden syndrome, a hereditary disorder characterized by a high risk of breast, thyroid, and colorectal cancers. Heterozygous PTEN loss can predispose to tumor development because of a “two-hit” mechanism, but some tumors exhibit loss of the remaining allele through somatic mechanisms.

PTEN-deficient tumors frequently display increased levels of phosphorylated AKT and mTOR signaling. Clinically, PTEN loss is associated with poorer prognosis and reduced overall survival in several cancer cohorts. Pathologists often assess PTEN status by immunohistochemistry or genetic sequencing to guide therapeutic decisions.

Therapeutic strategies targeting PTEN-deficient cancers focus on upstream or downstream components of the PI3K/AKT/mTOR axis. PI3K inhibitors (e.g., alpelisib), AKT inhibitors (e.g., capivasertib), and mTOR inhibitors (e.g., everolimus) have shown variable efficacy, sometimes in combination with hormonal or immune therapies. Synthetic lethal approaches exploiting defects in DNA damage response pathways, such as PARP inhibitors, are under investigation.

Ongoing research aims to refine PTEN diagnostic assays, understand tumor microenvironment interactions in PTEN-deficient contexts, and develop combination treatments to overcome resistance. The study of PTEN deficiency continues to provide insight into the molecular mechanisms of tumor suppression and offers potential avenues for targeted cancer therapy.